Efficacy and safety of semaglutide 24mg once weekly in adults with overweight or obesity and type2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 clinical trial
While recent federal actions have created some confusion, employers should understand that the core requirements of the Mental Health Parity and Addiction Equity Act (MHPAEA) remain in effect.
By improving blood sugar control, Semaglutide may help lower the risk of age-related metabolic conditions, including diabetes, cardiovascular disease, and major cardiac events such as heart attacks and strokes
For many post-GLP-1 patients, this procedure provides excellent results, particularly when the skin laxity is primarily below the belly button
Understanding these baseline risk factors is crucial for appropriate patient counseling and risk stratification
All chemicals were used as supplied